Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
RAAS inhibitors outperform CCBs in paediatric CKD, lowering kidney failure risk. Discover how this real-world study could shape first-line treatment. Read more.
The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results